MORAb-003, a fully humanized monoclonal antibody against the folate receptor alpha, for the potential treatment of epithelial ovarian cancer

Current Opinion in Investigational Drugs

Volumn 8, Issue 12, 2007, Pages 1067-1073

  Kalli, K R ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FOLATE RECEPTOR; MONOCLONAL ANTIBODY; MORAB 003; PLATINUM; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ALLERGIC REACTION; AMINO ACID SEQUENCE; ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CYTOTOXICITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG METABOLISM; DRUG SCREENING; FATIGUE; FEVER; HUMAN; MEDICAL TECHNOLOGY; MORPHOGENESIS; NONHUMAN; OVARY CANCER; REVIEW; RIGOR; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIBODIES, MONOCLONAL; CARRIER PROTEINS; CELL LINE, TUMOR; CHO CELLS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; CRICETINAE; CRICETULUS; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; EPITHELIAL CELLS; FATIGUE; FEMALE; FEVER; HUMANS; IMMUNOTHERAPY; INHIBITORY CONCENTRATION 50; MICE; MICE, NUDE; OVARIAN NEOPLASMS; RECEPTORS, CELL SURFACE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 36849091953     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. 365876 Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys. Zia-Amirhosseini P, Minthorn E, Benincosa LJ, Hart TK, Hottenstein CS, Tobia LA, Davis CB J PHARMACOL EXP THER 1999 291 3 1060-1067
2. 377030 Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Weitman SD, Lark RH, Coney LR, Fort DW, Frasca V, Zurawski VR, Kamen BA CANCER RES 1992 52 12 3396-3401
3. 477878 Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC et al N ENGL J MED 2003 348 3 252-254
4. 505391 DNA vaccination against the ovarian carcinoma-associated antigen folate receptor α (FRα) induces cytotoxic T lymphocyte and antibody responses in mice. Neglia F, Orengo AM, Cilli M, Meazza R, Tonmassetti A, Canevari S, Melani C, Colombo MP, Ferrini S CANCER GENE THER 1999 6 4 349-357
5. 553634 Morphotek and Baxter to codevelop anticancer antibody. Morphotek Inc PRESS RELEASE 2004 August 10
6. 604031 Phase I/II trial of the anti-idiotypic monoclonal antibody ACA125 in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer. Hilpert F, Harter P, Reinartz S, Sehouli J, Loibl S, Canzler U, Belau A, Reuss A, Jackisch C, Pfisterer J PROC AM SOC CLIN ONCOL 2005 24 Abs 5018
7. 651130 Dompe company website and pipeline. Dompe SpA COMPANY WORLD WIDE WEB SITE 2006 February 20
8. 669018 Phase I study of MORAb-003, a humanized anti-folate receptor-α monoclonal antibody, in platinum resistant ovarian cancer. Konner JA, Ahmed S, Gerst S, Vander Els N, Pezzuli S, Sabbatini P, Hensley M, Dupont J, Tew W, Aghajanian C PROC AM SOC CLIN ONCOL 2006 25 Abs 5027
9. 671536 MORAb-003 inhibits folate-driven growth mediated by the human folate receptor α. Routhier E, Turchin H, Patel R, Ebel W, Sass P, Nicolaides N, Grasso L PROC AM SOC CLIN ONCOL 2006 25 Abs 10108
10. 672641 Morphotek announces initiation of phase II clinical studies for MORAb-003 in ovarian cancer. Morphotek Inc PRESS RELEASE 2006 June 08
11. 672847 NCT00318370: Effectiveness of MORAb-003 in women with ovarian cancer who have relapsed after platinum-based chemotherapy. CLINICALTRIALS.GOV 2006 May 30
12. 675016 Morphotek announces orphan drug status granted for MORAb-003, a monoclonal antibody for the treatment of ovarian cancer. Morphotek Inc PRESS RELEASE 2006 June 21
13. 677451 Cancer statistics, 2006. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ CA CANCER J CLIN 2006 56 2 106-130
14. 737258 Tumor progression & therapeutic resistance - Third International Conference, Baltimore, MD, USA, 22-24 October 2006. Nicolaides NC IDDB MEETING REPORT 2006 October 22-24
15. 741097 VIRexx announces third quarter results. ViRexx Medical Corp PRESS RELEASE 2006 November 09
16. 769637 NCT00418574: Efficacy multicentre trial of immunotherapy vaccination with abagovomab to treat ovarian cancer patients. Menarini Group CLINICALTRIALS.GOV 2007 February 26
17. 785109 Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-α. Ebel W, Routhier EL, Foley B, Jacob S, McDonough JM, Patel RK, Turchin HA, Chao Q, Kline JB, Old LJ, Phillips MD et al CANCER IMMUNITY 2007 7 6-13 • At the time of publication, this was the only paper published in a peer-reviewed journal that specifically discusses MORAb-003. Both in vitro and in vivo preclinical studies are described, including toxicity studies in monkeys.
18. 785110 Human antibodies for immunotherapy development generated via a human B cell hybridoma technology. Li J, Sai T, Berger M, Chao Q, Davidson D, Deshmukh G, Drozdowski B, Ebel W, Harley S, Henry M, Jacob S et al PROC NATL ACAD SCI USA 2006 103 10 3557-3562
19. 798100 Novel phase II study design of MORAb-003, a monoclonal antibody against folate receptor α in platinum-sensitive ovarian cancer in first relapse. Phillips M, Armstrong D, Coleman R, Weil S, Arseneau J, Glenn D, Puls L, Senzer N, Torres J, White A AM SOC CLIN ONCOL 2007 43 Abs 5583
20. 798120 A phase I study of MORAb-003, a fully humanized monoclonal antibody against folate receptor α, in advanced epithelial ovarian cancer. Bell-McGuinn KM, Konner J, Pandit-Taskar N, Gerst S, Nicolaides N, Sass P, Grasso L, Weil S, Phillips M, Aghajanian C AM SOC CLIN ONCOL 2007 43 Abs 5553
21. 798330 Morphotek cleared to begin phase II ovarian cancer trial in Germany. Morphotek Inc PRESS RELEASE 2007 May 23
22. 820390 NCT00507741: Study of EC145 in patients with advanced ovarian and endometrial cancers. Endocyte Inc CLINICALTRIALS.GOV 2007 August 29
23. 827309 Endocyte company website and pipeline. Endocyte Inc COMPANY WORLD WIDE WEB SITE 2007 September 04
24. 830430 Overexpression of folate binding protein in ovarian cancers. Toffoli G, Cernigoi C, Russo A, Gallo A, Bagnoli M, Boiocchi M INT J CANCER 1997 74 2 193-198
25. 830436 Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Garin-Chesa P, Campbell I, Saigo PE, Lewis JL Jr, Old LJ, Rettig WJ AM J PATHOL 1993 142 2 557-567
26. 830437 Morphogenics as a tool for target discovery and drug development. Nicolaides NC, Ebel W, Kline B, Chao Q, Routhier E, Sass PM, Grasso L ANN NY ACAD SCI 2005 1059 86-96 • The rationale, procedures and potential uses of morphogenic technology are described in detail.
27. 830440 Current management strategies for ovarian cancer. Aletti GD, Gallenberg MM, Cliby WA, Jatoi A, Hartmann LC MAYO CLIN PROC 2007 82 6 751-770
28. 830442 Cancer of the ovary. Cannistra SA N ENGL J MED 2004 351 24 2519-2529
29. 830443 Comparative preclinical activity of the folate-targeted vinca alkaloid conjugates EC140 and EC145. Leamon CP, Reddy JA, Vlahov IR, Westrick E, Parker N, Nicoson JS, Vetzel M INT J CANCER 2007 121 7 1585-1592
30. 830444 Folate receptor specific anti-tumor activity of folate-mitomycin conjugates. Reddy JA, Westrick E, Vlahov I, Howard SJ, Santhapuram HK, Leamon CP CANCER CHEMOTHER PHARMACOL 2006 58 2 229-236
31. 830445 Folate receptor-mediated drug targeting: From therapeutics to diagnostics. Hilgenbrink AR, Low PS J PHARM SCI 2005 94 10 2135-2146
32. 99mTc-pteroate radiotracers for folate receptor-positive tumour targeting. Muller C, Hohn A, Schubiger PA, Schibli R EUR J NUCL MED MOL IMAGING 2006 33 9 1007-1016
33. 830447 Preparation and in vitro and in vivo evaluation of technetium-99m-labeled folate and methotrexate conjugates as tumor imaging agents. Okarvi SM, Jammaz IA CANCER BIOTHER RADIOPHARM 2006 21 1 49-60
34. 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: Initial clinical results. Siegel BA, Dehdashti F, Mutch DG, Podoloff DA, Wendt R, Sutton GP, Burt RW, Ellis PR, Mathias CJ, Green MA, Gershenson DM J NUCL MED 2003 44 5 700-707
35. 830449 Folate-mediated targeting of T cells to tumors. Roy EJ, Gawlick U, Orr BA, Kranz DM ADV DRUG DELIV REV 2004 56 8 1219-1231
36. 830450 Conjugates of folate and anti-T-cell-receptor antibodies specifically target folate-receptor-positive tumor cells for lysis. Kranz DM, Patrick TA, Brigle KE, Spinella MJ, Roy EJ PROC NATL ACAD SCI USA 1995 92 20 9057-9061
37. 830451 Synthesis and grafting of thioctic acid-PEG-folate conjugates onto Au nanoparticles for selective targeting of folate receptor-positive tumor cells. Dixit V, Van den Bossche J, Sherman DM, Thompson DH, Andres RP BIOCONJUG CHEM 2006 17 3 603-609
38. 830452 The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer. Hasegawa K, Nakamura T, Harvey M, Ikeda Y, Oberg A, Figini M, Canevari S, Hartmann LC, Peng KW CLIN CANCER RES 2006 12 20 Pt 1 6170-6178
39. 830453 T-cell immunity to the folate receptor α is prevalent in women with breast or ovarian cancer. Knutson KL, Krco CJ, Erskine CL, Goodman K, Kelemen LE, Wettstein PJ, Low PS, Hartmann LC, Kalli KR J CLIN ONCOL 2006 24 26 4254-4261
40. 830454 Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides. Peoples GE, Anderson BW, Fisk B, Kudelka AP, Wharton JT, Ioannides CG ANN SURG ONCOL 1998 5 8 743-750
41. 830455 Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers. Peoples GE, Anderson BW, Lee TV, Murray JL, Kudelka AP, Wharton JT, Ioannides CG CLIN CANCER RES 1999 5 12 4214-4223
42. 830456 Vaccination with dendritic cells transfected with mRNA-encoded folate-receptor-α for relapsed metastatic ovarian cancer. Hernando JJ, Park TW, Fischer HP, Zivanovic O, Braun M, Pölcher M, Grunn U, Leutner C, Potzsch B, Kuhn W LANCET ONCOL 2007 8 5 451-454
43. 830458 Recognizing and managing toxicities of molecular targeted therapies for colorectal cancer. Grothey A ONCOLOGY 2006 20 14 Suppl 10 21-28
44. 830460 Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. Goodell V, Salazar LG, Urban N, Drescher CW, Gray H, Swensen RE, McIntosh MW, Disis ML J CLIN ONCOL 2006 24 5 762-768
45. 830461 Gene transfection and expression of the ovarian carcinoma marker folate binding protein on NIH/3T3 cells increases cell growth in vitro and in vivo. Bottero F, Tomassetti A, Canevari S, Miotti S, Ménard S, Colnaghi MI CANCER RES 1993 53 23 5791-5796
46. 830462 Antisense oligonucleotides targeted to the human α folate receptor inhibit breast cancer cell growth and sensitize the cells to doxorubicin treatment. Jhaveri MS, Rait AS, Chung KN, Trepel JB, Chang EH MOL CANCER THER 2004 3 12 1505-1512
47. 830463 Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies. Figini M, Ferri R, Mezzanzanica D, Bagnoli M, Luison E, Miotti S, Canevari S GENE THER 2003 10 12 1018-1025
48. 830464 A review of folate receptor α cycling and 5-methyltetrahydrofolate accumulation with an emphasis on cell models in vitro. Kamen BA, Smith AK ADV DRUG DELIV REV 2004 56 8 1085-1097
49. 830465 Ascitic complement system in ovarian cancer. Bjorge L, Hakulinen J, Vintermyr OK, Jarva H, Jensen TS, Iversen OE, Meri S BR J CANCER 2005 92 5 895-905
50. 830466 Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumour cells. Junnikkala S, Hakulinen J, Jarva H, Manuelian T, Bjørge L, Bützow R, Zipfel PF, Meri S BR J CANCER 2002 89 10 1119-1127
51. 830467 Obstacles to cancer immunotherapy: Expression of membrane complement regulatory proteins (mCRPs) in tumors. Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M MOL IMMUNOL 2003 40 2-4 109-123
52. 830468 Folate receptor overexpression is associated with poor outcome in breast cancer. Hartmann LC, Keeney GL, Lingle WL, Christianson TJ, Varghese B, Hillman D, Oberg AL, Low PS INT J CANCER 2007 121 5 938-942
53. 830470 Overexpression of folate binding protein is associated with shortened progression-free survival in uterine adenocarcinomas. Allard JE, Risinger JI, Morrison C, Young G, Rose GS, Fowler J, Berchuck A, Maxwell GL GYNECOL ONCOL 2007 107 1 52-57
54. 830471 The folate receptor α is frequently overexpressed in osteosarcoma samples and plays a role in the uptake of the physiologic substrate 5-methyltetrahydrofolate. Yang R, Kolb EA, Qin J, Chou A, Sowers R, Hoang B, Healey JH, Huvos AG, Meyers PA, Gorlick R CLIN CANCER RES 2007 13 9 2557-2567
55. 830472 Folate receptor-targeted immunotherapy: Induction of humoral and cellular immunity against hapten-decorated cancer cells. Lu Y, Sega E, Low PS INT J CANCER 2005 116 5 710-719
56. 830473 Monoclonal antibody therapy of ovarian cancer. Nicodemus CF, Berek JS EXPERT REV ANTICANCER THER 2005 5 1 87-96
57. 831636 NCT00428766: Safety, tolerability and pharmacokinetics of MORAb-003 in subjects with advanced ovarian cancer. Morphotek Inc CLINICALTRIALS.GOV 2007 July 09
58. 835296 Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: A pilot study. van Zanten-Przybysz I, Molthoff C, Gebbinck JK, von Mensdorff-Pouilly S, Verstraeten R, Kenemans P, Verheijen R J CANCER RES CLIN ONCOL 2002 128 9 484-492
59. 835300 Escalating protein doses of chimeric monoclonal antibody MOv18 immunoglobulin G in ovarian carcinoma patients: A phase I study. Molthoff CF, Prinssen HM, Kenemans P, van Hof AC, den Hollander W, Verheijen RH CANCER 1997 80 12 Suppl 2712-2720
60. 835303 Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration. Buijs WC, Tibben JG, Boerman OC, Molthoff CF, Massuger LF, Koenders EB, Schijf CP, Siegel JA, Corstens FH EUR J NUCL MED 1998 25 11 1552-1561
61. 835305 The effect of folate fortification of cereal-grain products on blood folate status, dietary folate intake, and dietary folate sources among adult non-supplement users in the United States. Dietrich M, Brown CJ, Block G J AM COLL NUTR 2005 24 4 266-274
62. 835306 New tumor markers: CA125 and beyond. Bast RC Jr, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, Lokshin A et al INT J GYNECOL CANCER 2005 15 Suppl 3 274-281
63. 835307 Immunologic approaches to ovarian cancer treatment. Sabbatini P, Odunsi K J CLIN ONCOL 2007 25 20 2884-2893
64. 835308 Tumor-driven evolution of immunosuppressive networks during malignant progression. Kim R, Emi M, Tanabe K, Arihiro K CANCER RES 2006 66 11 5527-5536
65. 835324 Guidelines for referral of the patient with an adnexal mass. Gostout BS, Brewer MA CLIN OBSTET GYNECOL 2006 49 3 448-458